The ACAD11 antibody is a tool used to detect acyl-CoA dehydrogenase family member 11 (ACAD11), an enzyme belonging to the acyl-CoA dehydrogenase (ACAD) family, which plays a role in fatty acid metabolism. ACAD11 is implicated in the oxidation of very long-chain fatty acids (VLCFAs), though its precise substrates and biological functions remain under investigation. It localizes to mitochondria and shares structural features with other ACADs, such as FAD-binding domains and homotetrameric organization. Dysregulation of ACAD11 has been linked to mitochondrial disorders, metabolic imbalances, and neurodegenerative conditions, though its clinical significance is not yet fully defined.
Researchers utilize ACAD11 antibodies primarily in Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, tissue distribution, and subcellular localization. These studies aim to clarify ACAD11's role in cellular energy production, lipid homeostasis, and disease mechanisms. Recent interest has focused on its potential involvement in cancer progression and rare genetic disorders, as mutations in the ACAD11 gene may disrupt mitochondrial β-oxidation pathways. Commercial ACAD11 antibodies are typically raised against specific epitopes, often validated for reactivity in human or model organisms. However, variability in antibody specificity and batch consistency requires careful experimental controls. Ongoing research seeks to elucidate ACAD11's metabolic interactions and therapeutic relevance, positioning this antibody as a critical reagent in mitochondrial and metabolic disease studies.